Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  UroGen Pharma Ltd.    URGN   IL0011407140

UROGEN PHARMA LTD.

(URGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

UroGen Pharma : to Present at Jefferies Virtual Healthcare Conference

share with twitter share with LinkedIn share with facebook
06/01/2020 | 08:11am EDT

UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that Liz Barrett, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020, at 3:30 PM Eastern Time.

A live audio webcast of the event will be available on the Investors section of UroGen's website, www.urogen.com. A replay of the webcast will be available on the website for approximately two weeks.

About UroGen Pharma Ltd.
UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s approved Jelmyto™ (mitomycin) for pyelocalyceal solution, and pipeline treatment UGN-102 (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade non-muscle invasive bladder cancer, respectively. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.


© Business Wire 2020
share with twitter share with LinkedIn share with facebook
Latest news on UROGEN PHARMA LTD.
06/10UROGEN PHARMA LTD. : Changes in Registrant's Certifying Accountant, Change in Di..
AQ
06/08UROGEN PHARMA : Announces Inducement Grant under Nasdaq Listing Rule 5635(4)
AQ
06/05UROGEN PHARMA : Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
06/01UROGEN PHARMA : to Present at Jefferies Virtual Healthcare Conference
BU
05/18UROGEN PHARMA : Announces First Presentation of Data from Phase 2b Study of UGN-..
AQ
05/18UROGEN PHARMA : Announces Positive Data from Pivotal OLYMPUS Trial Evaluating Je..
AQ
05/15UROGEN PHARMA LTD. : Other Events (form 8-K)
AQ
05/15UROGEN PHARMA : Announces Positive Data from Pivotal OLYMPUS Trial Evaluating Je..
BU
05/15UROGEN PHARMA : Announces First Presentation of Data from Phase 2b Study of UGN-..
BU
05/07UROGEN PHARMA : Reports First Quarter 2020 Financial Results and Recent Corporat..
BU
More news
Financials (USD)
Sales 2020 12,5 M - -
Net income 2020 -137 M - -
Net cash 2020 17,7 M - -
P/E ratio 2020 -3,79x
Yield 2020 -
Capitalization 512 M 512 M -
EV / Sales 2019
EV / Sales 2020 39,4x
Nbr of Employees 174
Free-Float 87,6%
Chart UROGEN PHARMA LTD.
Duration : Period :
UroGen Pharma Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends UROGEN PHARMA LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 44,25 $
Last Close Price 23,35 $
Spread / Highest target 153%
Spread / Average Target 89,5%
Spread / Lowest Target 28,5%
EPS Revisions
Managers
NameTitle
Elizabeth Barrett President, Chief Executive Officer & Director
Arie S. Belldegrun Chairman
Peter P. Pfreundschuh Chief Financial Officer & Secretary
Moran Mieron Director-Research & Pre-Clinical Affairs
Mark P. Schoenberg Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
UROGEN PHARMA LTD.-30.03%512
GILEAD SCIENCES, INC.17.45%95 734
VERTEX PHARMACEUTICALS34.48%76 344
REGENERON PHARMACEUTICALS65.35%63 051
WUXI APPTEC CO., LTD.53.97%33 311
GENMAB A/S56.13%22 955